|
|
Blood, 15 September 2004, Vol. 104, No. 6, pp. 1784-1792.
Prepublished online as a Blood First Edition Paper on June 8, 2004; DOI 10.1182/blood-2004-01-0251.
Previous Article | Next Article 
Submitted January 27, 2004
Accepted April 20, 2004
Humoral immunity to HIV-1: Kinetics of antibody responses in chronic infection reflect capacity of immune system to improve viral set point
Alexandra Trkola*, Herbert Kuster, Christine Leemann, Annette Oxenius, Catherine Fagard, Hansjakob Furrer, Manuel Battegay, Pietro Vernazza, Enos Bernasconi, Rainer Weber, Bernard Hirschel, Sebastian Bonhoeffer, and Huldrych F Guenthard
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
Institute for Microbiology, ETH Zentrum Zurich, Zurich, Switzerland
Division of Infectious Diseases, University Hospital Geneva, Geneva, Switzerland
Division of Infectious Diseases, Inselspital Bern, Bern, Switzerland
Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland
Medizinische Klinik, University Hospital St Gallen, St Gallen, Switzerland
Division of Infectious Diseases, Ospedale Civico, Lugano, Switzerland
Institute of Ecology, ETH Zentrum Zurich, Zurich, Switzerland
* Corresponding author; email: alexandra.trkola{at}usz.ch.
We analyzed the humoral immune response in 46 patients following structured treatment interruption (STI) to investigate the general potential of therapeutic vaccination in chronic HIV-1 infection. Evoked antibody titer increases to gp120 and p24 were low during 4 short-term STIs and only reached significance during a 5th long-term interruption. Although induction of binding antibodies to viral antigens was not associated with potent suppression of viremia, we observed that individuals with a rapid and high response to p24, and to a lesser extent also to gp120, lowered their viral set points significantly. Of note, the increase of the anti-p24 response correlated with specific CD4 T helper frequency to this antigen. Despite induction of binding antibody responses, which correlated with improved viral control, the increase in neutralizing activity was marginal and did not lead to this enhanced viral suppression. However, a subgroup of patients who potently suppressed viremia independently of STI, had significantly higher pre-existing neutralization titers suggesting a role of humoral immunity in conferring potent protection. In summary, measuring the kinetics of antibody responses provided a marker to validate the responsiveness and capacities of the immune system of HIV-1 infected individuals and reflected the patients' ability to decrease viral set points.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Huber, V. von Wyl, C. G. Ammann, H. Kuster, G. Stiegler, H. Katinger, R. Weber, M. Fischer, H. Stoiber, H. F. Gunthard, et al.
Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked
J. Virol.,
April 15, 2008;
82(8):
3834 - 3842.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gorantla, H. Sneller, L. Walters, J. G. Sharp, S. J. Pirruccello, J. T. West, C. Wood, S. Dewhurst, H. E. Gendelman, and L. Poluektova
Human Immunodeficiency Virus Type 1 Pathobiology Studied in Humanized BALB/c-Rag2-/-{gamma}c-/- Mice
J. Virol.,
March 15, 2007;
81(6):
2700 - 2712.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Marcelino, H. Barroso, F. Goncalves, S. M. Silva, C. Novo, P. Gomes, R. Camacho, and N. Taveira
Use of a New Dual-Antigen Enzyme-Linked Immunosorbent Assay To Detect and Characterize the Human Antibody Response to the Human Immunodeficiency Virus Type 2 Envelope gp125 and gp36 Glycoproteins
J. Clin. Microbiol.,
February 1, 2006;
44(2):
607 - 611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Metzner, W. J. Moretto, S. M. Donahoe, X. Jin, A. Gettie, D. C. Montefiori, P. A. Marx, J. M. Binley, D. F. Nixon, and R. I. Connor
Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus
J. Gen. Virol.,
December 1, 2005;
86(12):
3375 - 3384.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. P Galvani
The role of mutation accumulation in HIV progression
Proc R Soc B,
September 7, 2005;
272(1574):
1851 - 1858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Joos, A. Trkola, M. Fischer, H. Kuster, P. Rusert, C. Leemann, J. Boni, A. Oxenius, D. A. Price, R. E. Phillips, et al.
Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions
J. Virol.,
July 15, 2005;
79(14):
9026 - 9037.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Rusert, H. Kuster, B. Joos, B. Misselwitz, C. Gujer, C. Leemann, M. Fischer, G. Stiegler, H. Katinger, W. C. Olson, et al.
Virus Isolates during Acute and Chronic Human Immunodeficiency Virus Type 1 Infection Show Distinct Patterns of Sensitivity to Entry Inhibitors
J. Virol.,
July 1, 2005;
79(13):
8454 - 8469.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|